Trial Profile
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2019
Price :
$35
*
At a glance
- Drugs MDT 637 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 25 Jan 2019 Status changed from recruiting to completed.
- 27 Apr 2012 New trial record